<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001397906</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001612042</issuerCik>
      <issuerName>Ascendis Pharma A/S</issuerName>
      <secFileNumber>001-36815</secFileNumber>
      <issuerAddress>
        <com:street1>TUBORG BOULEVARD 12</com:street1>
        <com:city>HELLERUP</com:city>
        <com:stateOrCountry>P7</com:stateOrCountry>
        <com:zipCode>1105 BP</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>45 70 22 22 44</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Cha Albert</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>CITIGROUP GLOBAL MARKETS</name>
        <address>
          <com:street1>390 GREENWICH ST</com:street1>
          <com:city>NEW YORK</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>2100</noOfUnitsSold>
      <aggregateMarketValue>508389.00</aggregateMarketValue>
      <noOfUnitsOutstanding>61977408</noOfUnitsOutstanding>
      <approxSaleDate>03/02/2026</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>03/02/2026</acquiredDate>
      <natureOfAcquisitionTransaction>RESTRICTED STOCK VESTING</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>ASCENDIS PHARMA A/S</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>3575</amountOfSecuritiesAcquired>
      <paymentDate>03/02/2026</paymentDate>
      <natureOfPayment>COMPENSATION</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks> FOR SECTION 3D THE INDICATIVE MARKET PRICE IS 242.09. SHARES BEING SOLD FOR THE VESTING AND SETTLEMENT OF EQUITY AWARDS. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS DATES.THE INTENDED NUMBER OF SHARES IS AN APPRROXIMATION DUE TO MARKET CONDITIONS. THE SALES WILL TAKE PLACE OVER MULTIPLE TRADING DAYS.THESE ARE NON DISCRETIONARY TRANSACTIONS. THESE ARE BEING PERFORMED UNDER AN ESTABLISHED 10B51 PLAN</remarks>
    <noticeSignature>
      <noticeDate>03/02/2026</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>09/07/2023</planAdoptionDate>
      </planAdoptionDates>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
